Vinge Logotype
SvenskaEnglish 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge advisor in connection with Klarna's IPO on the New York Stock Exchange
Mandate

Vinge advisor in connection with Klarna's IPO on the New York Stock Exchange

September 15, 2025 M&A Capital Markets and Public M&A Financial Regulatory Corporate Tax

Vinge, together with Latham & Watkins, acted as advisor to bookrunners and managers in connection with the listing of Klarna, the global digital bank and provider of flexible payment solutions, on the New York Stock Exchange.

The first day of trading was September 10, 2025, and Klarna set the price for its IPO at US$40 per share, valuing the company at approximately US$15 billion.

More information about the IPO can be found here: https://www.klarna.com/international/press/klarna-lists-on-the-new-york-stock-exchange/

Vinge's team consisted mainly of Johan Larsson (Corporate), Jesper Schönbeck, Amanda Knutsson and Anna Svensson (Equity Capital Markets), Emma Stuart-Beck, Henrik Schön and David Flodin (Regulatory) and Victor Ericsson, Erik Kochbati and Marcus Svärd (Tax).

Related

Vinge advises Intera Partners’ portfolio company Yellow Elk in connection with its acquisition of Bizware

 Vinge has advised the Nordic private equity firm Intera Partners’ portfolio company Yellow Elk in connection with its acquisition of the data analytics and AI firm Bizware AB and its subsidiaries Bizware Lead AB and Bizware Nova AB.
September 11, 2025

Vinge has acted as local counsel supporting lead counsel Latham & Watkins in advising Cadence in connection with its acquisition of Hexagon’s Design & Engineering Business for approx. EUR 2.7 billion

 Cadence (Nasdaq: CDNS) announced it has entered into a definitive agreement to acquire the Design & Engineering business of Hexagon AB, which includes its MSC Software business—a pioneer in engineering simulation and analysis solutions.
September 09, 2025

Vinge has advised Oncopeptides in connection with its rights issue

 Vinge has advised Oncopeptides AB (publ) in connection with a fully guaranteed rights issue which will provide Oncopeptides with proceeds of approximately SEK 150 million before deduction of transaction costs.
August 28, 2025